# Early Intracoronary N-Acetylcysteine During Primary PCI in STEMI: A Pilot Randomized Trial of Reperfusion Injury Biomarkers and Functional Recovery

Study · id `cardio:ct-nct06850831` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06850831](<https://clinicaltrials.gov/study/NCT06850831>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06850831

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT06850831. Randomized; double masking; primary purpose treatment. Start 2025-04-01 (actual); primary completion 2026-03-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT06850831, source copy `cardio:ctgov-nct06850831-2026-10-02`, retrieved 2026-10-26)
- Started: 2025-04-01 (actual) (ClinicalTrials.gov record NCT06850831, source copy `cardio:ctgov-nct06850831-2026-10-02`, retrieved 2026-10-26)
- Primary completion: 2026-03-30 (actual) (ClinicalTrials.gov record NCT06850831, source copy `cardio:ctgov-nct06850831-2026-10-02`, retrieved 2026-10-26)
- Completion: 2026-04-30 (actual) (ClinicalTrials.gov record NCT06850831, source copy `cardio:ctgov-nct06850831-2026-10-02`, retrieved 2026-10-26)
- Countries: Indonesia (ClinicalTrials.gov record NCT06850831, source copy `cardio:ctgov-nct06850831-2026-10-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06850831-2026-10-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Early Intracoronary N-Acetylcysteine During Primary PCI in STEMI: A Pilot Randomized Trial of Reperfusion Injury Biomarkers and Functional Recovery
- Condition: STEMI - ST Elevation Myocardial Infarction (MI)
- Condition: Primary PCI - STEMI
- Intervention (Drug): Antipac
- Lead sponsor: dr. Ahmad Yasa, Sp.JP, Subsp.K.I.(K), M.Kes, FIHA, FasCC, FA
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

## Provenance

Content hash: b56857bde8faf619128c9c0e2442b2609b1c4c8c85893549b393f30bcf4c4ff5
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
